Loading clinical trials...

UNKNOWNNA

Repetitive Transcranial Magnetic Stimulation for the Treatment of Negative Symptoms in Schizophrenia Patients.

A Randomized Double-blind Controlled Study of Repetitive Transcranial Magnetic Stimulation (rTMS) for the Treatment of Negative Symptoms in Schizophrenia Patients.

NCT02842034•Shanghai Mental Health Center

View on ClinicalTrials.gov

Summary

This study is to determine whether high frequency repetitive transcranial magnetic stimulation (rTMS) is effective in the treatment of negative symptoms in schizophrenia patients

Detailed Description

The principal objective of this trial is to investigate the effect of high frequency rTMS on negative symptoms in schizophrenia.

Eligibility

Age

15 - 55 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•The diagnosis of schizophrenia according to DSM-IV；
•18～55 years old；
•schizophrenic illness duration longer than one year;
•The sum of negative scores in the range Positive and negative symptom score (PANSS) must be 20 points or higher, at least one item from the area of negative symptoms (N1-N7) must be ≥ 4 points (at least moderate, clinically significant symptoms), and improvement in negative symptom-sum (measuring by PANSS) must be 10% or lower during the last two weeks before rTMS stimulation.
•Have a stable and consistent drug treatment at least two weeks prior the rTMS treatment;
•Able to adhere to the treatment schedule;
•IQ≥80;
•Dextromanual, normal vision and hearing;
•Signed an informed consent

Exclusion Criteria

•rTMS contraindications: intracranial metal substance, with heart pacemakers and cochlear implants, intracranial pressure;
•Acute risk of suicide and impulse；
•patients to be diagnosed according to DSM-IV for substance abused, development delayed;
•suffering from serious physical disease and can not accept the treatment;
•history of epileptic seizures or the presence of epileptic activity documented on the basis of EEG;
•difficult to maintain the current drug treatment for at least 1 month;
•undergoing ECT or MECT in last 3 months;
•current treatment with anticonvulsant acting drugs such as anticonvulsants, benzodiazepines.

Locations (1)

Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine

Shanghai, Shanghai Municipality, China

Key Dates

Start Date

July 1, 2016

Primary Completion Date

July 1, 2018

Completion Date

December 1, 2018

Last Updated

February 26, 2018

Enrollment

ESTIMATED participants

Conditions

Schizophrenia

Interventions

Repetitive Transcranial Magnetic Stimulation

DEVICE

Contacts

Dengtang Liu, MD

CONTACT

+86 21 64387250-73775 erliu110@126.com

Feasibility, Acceptability, and Preliminary Efficacy of Yoga-based Group Intervention for Outpatients With Schizophrenia Spectrum Disorders

NCT07455929

Psychotic DisordersSchizophrenia Spectrum Disorders

View study

RECRUITING

Biomarkers/Biotypes, Course of Early Psychosis and Specialty Services

NCT06740383

Schizophrenia Spectrum and Other Psychotic DisordersSchizophrenia+5 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 26, 2018Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Repetitive Transcranial Magnetic Stimulation for the Treatment of Negative Symptoms in Schizophrenia Patients.

Inclusion Criteria

Exclusion Criteria

Feasibility, Acceptability, and Preliminary Efficacy of Yoga-based Group Intervention for Outpatients With Schizophrenia Spectrum Disorders

Biomarkers/Biotypes, Course of Early Psychosis and Specialty Services

A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Inpatient Adults With Schizophrenia

Acceptability, Feasibility and Preliminary Outcomes of the Kiso Mind App for Outpatients With Schizophrenia Spectrum Disorders

Brain Stimulation to the Hippocampus in Schizophrenia

Develop a Novel Occupational Training Program for Schizophrenia Patients Based on Virtual Reality Techniques